Edwards Lifesciences divests hemofiltration product business to Baxter International

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the sale of certain assets related to its hemofiltration product line to Baxter International Inc. (NYSE: BAX), consistent with the previously announced terms of the agreement.

"The completion of this transaction allows us to better focus resources on our strategic initiatives while benefitting Edwards' hemofiltration employees, products and customers," said Carlyn D. Solomon, Edwards' corporate vice president, Critical Care and Vascular.

Source:

Edwards Lifesciences

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 20). Edwards Lifesciences divests hemofiltration product business to Baxter International. News-Medical. Retrieved on February 04, 2023 from https://www.news-medical.net/news/20090902/Edwards-Lifesciences-divests-hemofiltration-product-business-to-Baxter-International.aspx.

  • MLA

    Baxter International Inc.. "Edwards Lifesciences divests hemofiltration product business to Baxter International". News-Medical. 04 February 2023. <https://www.news-medical.net/news/20090902/Edwards-Lifesciences-divests-hemofiltration-product-business-to-Baxter-International.aspx>.

  • Chicago

    Baxter International Inc.. "Edwards Lifesciences divests hemofiltration product business to Baxter International". News-Medical. https://www.news-medical.net/news/20090902/Edwards-Lifesciences-divests-hemofiltration-product-business-to-Baxter-International.aspx. (accessed February 04, 2023).

  • Harvard

    Baxter International Inc.. 2019. Edwards Lifesciences divests hemofiltration product business to Baxter International. News-Medical, viewed 04 February 2023, https://www.news-medical.net/news/20090902/Edwards-Lifesciences-divests-hemofiltration-product-business-to-Baxter-International.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Pacritinib for myelofibrosis meets primary endpoint in Phase 3 PERSIST-1 trial